Skip to content

Effect of Rg1-based Supplementation on Exercise Training-induced Stem Cell Recruitments and Skeletal Muscle Adaptation in Women Aged > 60

Effect of Rg1-based Supplementation on Exercise Training-induced Stem Cell Recruitments and Skeletal Muscle Adaptation in Women Aged > 60

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07703774
Acronym
Senactiv
Enrollment
60
Registered
2026-07-14
Start date
2026-08-02
Completion date
2029-01-02
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloid Cell Infiltration

Keywords

Nestin+ cells, Neural stem cells, Acetylcholine receptor

Brief summary

This study will provide novel insights into the role of bone marrow-derived stem cells in muscle adaptation to long-term exercise and advance our understanding of an Rg-1 based supplement-Senactiv® as a potential intervention for preventing sarcopenia and cognitive decline in older adults.

Detailed description

Background: We have recently observed increased mesenchymal stem cells (Stro-1+ MSCs) in exercised skeletal muscle in women \> 60 years following consumption of a ginseng-derived Rg1-based supplement (Senactiv®). A substantial proportion of these mobilized stem cells differentiated into neural stem cells (Nestin+). Exercise-induced sex hormone depletion is completely attenuated. Together with our earlier finding that Senactiv® reduced perceived exertion during resistance exercise in young men, these results suggest that the supplement may enhance brain-muscle connection/rewiring to improve performance. This acute, single-dose study raises the important question of whether long-term Senactiv® consumption can augment muscle strength and mass in older women engaged in resistance training, a population at high risk of progressing into sarcopenia. Study Design: To address this, we will conduct a 12-week, two-arm, randomized, double-blind, placebo-controlled trial. Primary and secondary outcomes will include muscle strength, perceived exertion, muscle mass, grip strength and sitting-rising test, sex hormones, Nestin+ neural stem cells, mitochondria-rich phagocytes (MPO-expressing cells), transcriptomic changes (RNA-seq) focusing on age-related biomarkers, bone marrow-derived cells and cognitive function. Skeletal muscle tissue will be analyzed using minimally invasive micro-biopsy at three time points: pre-exercise baseline, immediately after the first exercise bout (0 h, acute response), and 48 hours after the final training session (long-term adaptation). Cognitive function will be comprehensively assessed using available campus resources.

Interventions

BEHAVIORALResistance exercise

4 sets of 8-RM leg squats

Sponsors

University of Taipei
Lead SponsorOTHER
Education University of Hong Kong
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Care providers will administer either the placebo or the treatment to participants without knowledge of the pill centent allocation. The placebo and treatment pills will be manufactured to be indistinguishable in appearance, ensuring blinding of both care providers and participants.

Intervention model description

Randomized controlled trial of Rg1 and Placebo supplementation

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

\- Must be able to swallow pills

Design outcomes

Primary

MeasureTime frameDescription
Bone marrow derived cells in skeletal muscle* 3 weeks before exercise (baseline) * Immediately after exercise (0 hour) * 1-hour after exercise (1 h) * 24-hour after exercise (24 h)Cell markers with bone marrow identity

Contacts

CONTACTChia-Hua Kuo, PhD
kuochiahua@gmail.com+85263057921

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026